Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Multivariable analyses of global expression profiling are valid indicators of the prognosis of various diseases including brain cancers. To identify the candidates for markers of prognosis of
glioblastoma
, we performed multivariable analyses on the status of epithelial (EPI)-mesenchymal (MES) transition (EMT), glioma (GLI) stem cells (GSCs), molecular target therapy (MTT), and potential glioma biomarkers (PGBs) using the expression data and clinical information from patients. Random forest survival and Cox proportional hazards regression analyses indicated significant variable values for
DSG3
,
CLDN1
,
CDH11
,
FN1
,
HDAC3/7
,
PTEN
,
L1CAM
,
OLIG2
,
TIMP4
,
IGFBP2
, and
GFAP
. The analyses also comprised prognosis prediction formulae that could distinguish between the survival curves of the
glioblastoma
patients. In addition to the genes mentioned above,
HDAC1
,
FLT1
,
EGFR
,
MGMT
,
PGF
,
STAT3
,
SIRT1
, and
GADD45A
constituted complex genetic interaction networks. The calculated status scores obtained by principal component analysis indicated that GLI genes covered the status of EPI, GSC, and MTT-related genes. Moreover, survival tree analyses indicated that MES
high
, MES
high
GLI
low
, GSC
high
GLI
low
, MES
high
MTT
low
, and PGB
high
showed poor prognoses and MES
middle
, GSC
low
, and PGB
low
showed good prognoses, suggesting that enhanced EMT and GSC are associated with poor survival and that lower expression of EPI markers and the pre-stages of EMT are relatively less malignant in
glioblastoma
. These results demonstrate that the assessment of EMT and GSC enables the prediction of the prognosis of
glioblastoma
that would help develop novel therapeutics and de novo marker candidates for the prognoses of
glioblastoma
.
...
PMID:Promising Prognosis Marker Candidates on the Status of Epithelial-Mesenchymal Transition and Glioma Stem Cells in Glioblastoma. 3165 34
Glioblastomas
are the most common primary central nervous system malignancy tumor in adults.
Glioblastoma
patients have poor prognosis, with an average survival period of approximately 14 mo after diagnosis. To date, there are a limited number of effective treatment methods for
glioblastoma
, and its molecular mechanisms remain elusive. In this article, we analyzed the key biomarkers and pathways in
glioblastoma
patients based on gene expression and DNA methylation datasets. The 60 hypomethylated/upregulated genes and 110 hypermethylated/downregulated genes were identified in GSE50923, GSE50161, and GSE116520 microarrays. Functional enrichment analyses indicated that these methylated-differentially expressed genes were primarily involved in collagen fibril organization, chemical synaptic transmission, extracellular matrix-receptor interaction, and GABAergic synapse. The hub genes were screened from a protein-protein interaction network; in selected genes, increased NMB mRNA level was associated with favorable overall survival, while elevated CHI3L1, POSTN, S100A4, LOX, S100A11,
IGFBP2
, SLC12A5, VSNL1, and RGS4 mRNA levels were associated with poor overall survival in
glioblastoma
patients. Additionally, CHI3L1, S100A4, LOX, and S100A11 expressions were negatively correlated with their corresponding methylation status. Furthermore, the receiver-operator characteristic curve analysis indicated that CHI3L1, S100A4, LOX, and S100A11 can also serve as highly specific and sensitive diagnostic biomarkers for
glioblastoma
patients. Collectively, our study revealed the possible methylated-differentially expressed genes and associated pathways in
glioblastoma
and identified four DNA methylation-based biomarkers of
glioblastoma
. These results may provide insight on diagnostic and prognostic biomarkers, and therapeutic targets in
glioblastoma
.
...
PMID:DNA Methylation-based Diagnostic and Prognostic Biomarkers for Glioblastoma. 3251 Feb 39
<< Previous
1
2
3
